Dr Sammons on the SONIA Trial of First-Line CDK4/6 Inhibitor Use in HR+/HER2– Breast Cancer

Sarah Sammons, MD, discusses whether CDK4/6 inhibitors should be considered a standard first line treatment within hormone receptor–positive, HER2-negative advanced breast cancer according to primary results from the phase 3 SONIA trial.

Related Keywords

Sarah Sammons ,Dana Farber Cancer Institute ,Metastatic Breast Cancer Program ,Estrogen Receptor Positive ,Er2 Negative Advanced Or Metastatic Breast Cancer ,Cdk4 6 Inhibitors ,Phase 3 Sonia Trial ,Hormone Receptor Hr Positive ,Er2 Negative Advanced Breast Cancer ,